The Bristol-Myers Squibb-Pfizer Alliance and Fitbit collaborate to address gaps in atrial fibrillation detection with the aim of accelerating diagnosis
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of atrial fibrillation (AFib) with the aim of improving earlier detection in individuals at increased risk of stroke.
Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
- Details
- Category: AstraZeneca
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review.
Novartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host disease
- Details
- Category: Novartis
Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-host disease (GvHD). The study met its primary endpoint of superior overall response rate (ORR) at day 28 of treatment with Jakavi, compared with best available therapy (BAT)[1].
Sanofi opens its first digitally-enabled, continuous manufacturing facility; ushers in next generation of biotech manufacturing
- Details
- Category: Sanofi
Sanofi today celebrates the inauguration of its new digital manufacturing facility in Framingham, Massachusetts, marking one of the world's first digital facilities using intensified, continuous biologics production technology. The new facility features leading-edge technology that connects the production process with research and development, paving the way for improved commercialization of important new medicines for patients.
Abbott and Omada Health partner to offer integrated digital health and coaching experience for people with Type 2 diabetes
- Details
- Category: Abbott
Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digital care program, aiming to create a new paradigm for people with Type 2 diabetes.
Bayer inks deals with eleven startups under G4A Digital Health Partnerships program
- Details
- Category: Bayer
Bayer announced today that the company has signed collaboration agreements with eleven digital health startups. As part of the program, Bayer will support these startup companies aiming for longer-term collaborations to drive forward the development of specific digital solutions to improve patients' health in the fields of cardiovascular diseases, oncology, ophthalmology, pulmonology, radiology as well as digital therapeutics.
Abbott and Abbott Fund launch 'Future Well Kids' program to help students shape healthier lives
- Details
- Category: Abbott
Abbott and its foundation, the Abbott Fund, launched Future Well™ Kids, a program designed to educate and inspire middle school students ages 10-13 to learn about the causes of chronic disease and adopt healthy habits to live healthier, fuller lives.
Chronic diseases, also known as noncommunicable diseases (NCDs) such as diabetes and cardiovascular disease, are the leading cause of death around the world.
More Pharma News ...
- Akcea and Pfizer Inc. announce licensing agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
- Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
- AstraZeneca divests rights for Losec to Cheplapharm
- Ian Read to retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla named Chairman
- Brilinta monotherapy in high-bleeding risk patients who underwent PCI had reduced risk of clinically relevant bleeding than with dual antiplatelet therapy in the TWILIGHT trial
- Amgen announces positive results from two Phase 3 BLINCYTO® (blinatumomab) studies In pediatric patients with relapsed acute lymphoblastic leukemia
- Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital open joint lab for research of new treatments for chronic lung diseases